FDA Issues Complete Response Letter Cosibelimab for Cutaneous Squamous Cell Carcinoma
The FDA has issued a complete response letter to the biologic license application seeking the approval of cosibelimab for use in patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not eligible for curative surgery or radiation.
Kaplan Meier James Olivero Checkpoint Therapeutics Inc Drug Administration Prescription Drug User Fee Checkpoint Therapeutics
Source: onclive.com